Bone drugs' safety doubted

Share this article:
A new U.S. Food and Drug Administration analysis raises questions about long-term effectiveness among women of the widely prescribed osteoporosis drugs known as bisphosphonates.

The safety of the bone-building drugs, which include brands such as Boniva and Reclast, has been a topic of debate. The FDA's analysis found that after three to five years of use, bisphosphonates offer little to no benefit.

FDA reviewers said it's possible long-term use of the drugs could actually weaken bones, leading to adverse events such as femur fractures and esophageal cancer.
Share this article:
close

Next Article in News

More in News

Antipsychotics reduction goal is 25% by end of 2015, CMS and provider groups announce

Antipsychotics reduction goal is 25% by end of ...

Long-term care providers are being asked to reduce the use of antipsychotic medications among residents by 25% by the end of 2015, and 30% by the end of 2016. Providers ...

CDC issues new guidelines on pneumococcal vaccine, says LTC flu vaccination rates remain low

CDC issues new guidelines on pneumococcal vaccine, says ...

Long-term care workers continued to have low rates of flu vaccination last season, despite there being 92% vaccination coverage overall among physicians and nurses, the Centers for Disease Control and ...

AL operators accused of withholding $2M in unpaid overtime, minimum wages ...

Four California assisted living operators are facing eight felony charges related to wage theft, tax and insurance violations, according to local reports.